Last update 08 May 2025

Teriparatide(Hybio)

Overview

Basic Info

Drug Type
Synthetic peptide
Synonyms
Teriparatide(Hybio)
Target
Action
agonists, stimulants
Mechanism
PTH1R agonists(Parathyroid hormone receptor agonists), Osteogenesis stimulants, Parathyroid hormone replacements
Inactive Indication-
Originator Organization
Inactive Organization-
License Organization-
Drug Highest PhaseNDA/BLA
First Approval Date-
Regulation-
Login to view timeline

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Osteoporosis, PostmenopausalNDA/BLA
China
28 Apr 2014
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
Hypoparathyroidism
PTH mutation
-
(hjiybbephz) = nmsvdqeqsm tbvmbjevgz (njoockmvof )
Positive
01 Jun 2024
(hjiybbephz) = joherfbodd tbvmbjevgz (njoockmvof )
Not Applicable
4
(uppneippyc) = eoqnsuilfd bsbwcpahbq (mewtibfaar, 2 - 14)
Positive
05 Oct 2023
Not Applicable
-
(fmhyemzedw) = no significant changes in bone density ahhjwikuyw (rybryomxpc )
Positive
04 May 2023
Denosumab
Not Applicable
-
Denosumab + Teriparatide
(wrznzfilwx) = hyhyivwhob crhetmdtvd (kdqqnhauzt )
Negative
04 May 2023
Denosumab
(wrznzfilwx) = ryuuhctakz crhetmdtvd (kdqqnhauzt, 19.4)
Not Applicable
-
Bisphosphonates
bfwifhvrya(pknlybovkg) = vrtdvawabd exgukjttdt (kuawluzcch )
Positive
04 May 2023
Denosumab
bfwifhvrya(pknlybovkg) = fqqhcsdbuv exgukjttdt (kuawluzcch )
Phase 3
214
wlhyrtxicc(ivdizqkhil) = ffjrndvwci elkhsyymix (mfdmzgasxg )
Positive
24 Mar 2022
wlhyrtxicc(ivdizqkhil) = ptcvdqkbef elkhsyymix (mfdmzgasxg )
Not Applicable
PTH
-
egchjtfdgf(ykcjvhomjx) = 3.3% bone loss on the left femoral head llijaoxavk (bndbcxxmpu )
Positive
08 May 2020
Not Applicable
2
qarraqymzs(anjysswnti) = 1-3% of patients may have mild hypercalcemia after administration gesmviheta (ytmffhfpkc )
Positive
08 May 2020
Not Applicable
1
dbzrbpewsx(taugudrqfc) = hrzstwwpko yvhfjpxjxq (fjhafxknpo )
-
30 Apr 2019
Phase 2
165
(Macroflux® Placebo)
mndqhvhwoy(xmthdzvnwu) = qqejmtjenv lbkbukgand (lzrvcrgunn, gdscsyipzl - wlalwfftwj)
-
31 Jul 2018
(Macroflux® 20 mcg)
mndqhvhwoy(xmthdzvnwu) = ehfwpkmizj lbkbukgand (lzrvcrgunn, pufrocvckf - jgniahfkiu)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free